

## Formulation of Bod's proprietary trial ready cannabis sublingual wafer complete

- R&D process for cannabis sublingual wafer which will be tested in Phase I Clinical trial finalised
- Manufacture of Clinical Trial cannabis stock to commence in coming weeks - trial to begin shortly thereafter
- Combination of Bod's proprietary ECs315 extract and patent protected WaferiX technology leaves Bod with a globally unique cannabis product - export and licencing agreements actively being pursued
- ECs315 CBD extract in MCT oil expected to arrive in coming weeks - Company to distribute through TGA's Special Access scheme Category B
- Company liaising with authorised prescribers to ensure efficient distribution of CBD oil
- Vertical expansion opportunities being assessed - discussions with strategic partners progressing

**Sydney, Australia – 11 May 2018:** Developer and distributor of natural, evidence-based cosmetics, natural medicines and health products, Bod Australia Limited ("Bod" or the "Company") (ASX: BDA) is pleased to advise that the Company's proprietary, sublingual cannabis wafer has been formulated by specialty pharmaceutical company and exclusive partner, iX Biopharma. Manufacture of required cannabis Clinical Trial stock is set to commence in the coming weeks, with Phase I Clinical trials to commence shortly thereafter.

The wafer is a unique combination of Bod's proprietary ECs315 cannabis extract and exclusive partner, iX Biopharma's 'WaferiX' technology. The formulated product, containing Bod's proprietary cannabis extract, which has been freeze dried into a sublingual wafer, can be placed under the patient's tongue. The wafer dissolves rapidly and releases contained active compounds for efficient absorption.

The upcoming Phase I Clinical trial will test the safety, tolerability and pharmacokinetics of Bod's proprietary ECs315 extract presented as a sublingual wafer. A positive trial outcome will leave the Company with a unique, patent protected, standardised and reproducible cannabis product which maybe sold or licenced to major pharmaceutical companies.

The Company is actively exploring potential licence and export opportunities for Medicabilis in WaferiX form and will update shareholders should any developments materialise.

Further, the Company expects to receive Linnea's proprietary ECs315, 5% CBD in MCT oil in the coming weeks, which is being imported following permission from the Office of Drug Control (refer ASX announcement: 12 April 2018). Following delivery, Bod will make the oil available to patients through the Therapeutic Goods Administration (TGA) Special Access Scheme Category B.

To allow absolute transparency around the product, Bod will embark on a professional education program for all relevant specialists and eligible pharmacies ensuring efficient prescription and dispensing of the scheduled product. Further, the Company will implement consistent education and support initiatives for all parties involved in the prescription and dispensing of CBD oils.

**Bod Australia CEO Jo Patterson said:** “Having finalised the formulation of Medicabilis in WaferiX form we have another major milestone for the Company as it tracks towards the commencement of its Phase I Clinical Trial program.

“The formulation process has left Bod with a unique, standardised and reproducible cannabis product and we look forward to completing manufacture of our trial stock in the coming weeks.

“Following potentially successful trial results, the Company will have a significant global opportunity to distribute and licence the cannabis sublingual wafer and look to capitalise on this to deliver value for shareholders.

“As well, we look forward to receiving our initial order of cannabis oils into Australia and ensuring that it is prescribed and distributed, not only to those that require it, but also in a fully transparent manner.

“The Company looks to commence educational and support initiatives to all relevant specialists and pharmacies as soon as possible and to progress agreements, where applicable, for centralised distribution points through approved pharmacies.

“Board and management look forward to updating shareholders on the Company’s progress in the coming weeks.”



**Image one:** Formulated Medicabilis in WaferiX form for use in Clinical trials



**Image two:** Bod Australia’s proposed packaging for the ECs315 CBD extract in MCT oil

For more information: [bodaustralia.com](http://bodaustralia.com)

- ENDS -

## **About Bod Australia**

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics, natural medicines and health supplements, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 900 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia is also building a sustainable, multi-faceted cannabis business through a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

## **For more information please contact:**

Jo Patterson

Bod Australia

+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations

[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)

+61 431 271 538